All news

For more information on Coronavirus disease 2019

30 March, 2020

COVID-19 Corona Virus South African Resource Portal:

E.g., 06/03/2020
E.g., 06/03/2020

bioMérieux Completes its VIDAS® Hepatitis Panel with a New Test for the Diagnosis of Hepatitis C

03 May, 2012

bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of VIDAS® Anti-HCV for the detection of the hepatitis C virus (HCV). With this new CE marked test, VIDAS® now has a complete hepatitis menu with tests for A, B and C viral hepatitis.

bioMérieux’s Myla® Named as Finalist in the 2012 Medical Design Excellence Awards

12 April, 2012

A world leader in in vitro diagnostics, bioMérieux today announced that its microbiology middleware, Myla® has been selected as a finalist in the In Vitro Diagnostics category of the Medical Design Excellence Awards (MDEA)competition. Myla is an innovative microbiology middleware solution that offers consolidated interfacing, workflow optimization and information management. Myla is browser-based and consolidates information that can impact patient care and efficiency from ID/AST and blood culture testing in a single interface for the LIS. Users can access Myla remotely from anywhere on their network.

bioMérieux Initiative to Support European Antibiotic Awareness Day

18 November, 2011

As the world leader in microbiology and a pioneer in diagnostics for antimicrobial resistance detection and susceptibility testing (AST), bioMérieux actively supports the annual European Antibiotic Awareness Day, organized today by the ECDC.1 bioMérieux subsidiaries throughout the world are providing educational tools for healthcare professionals to help increase public awareness about this serious issue.

bioTheranostics’ CancerTYPE ID® Linked with Improved Clinical Outcome and Longer Survival

08 November, 2011

bioTheranostics, Inc., a bioMérieux company that develops innovative oncology diagnostic tests to drive personalized treatment, today announced clinical study findings that link CancerTYPE ID® molecular testing with improved patient outcome. Patients in which CancerTYPE ID predicted a colorectal site of origin that subsequently received site-specific therapy had a median survival three times that of what has been reported in patients treated empirically for cancer of unknown primary (CUP). These results make CancerTYPE ID the only marketed molecular cancer classifier to demonstrate therapeutic response and patient benefit based on molecular tumor profiling.

bioMérieux Expands its Infectious Disease Offering with Acquisition of ARGENE, Specialized in Molecular Diagnostics for Immunocompromised Patients

19 July, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, announced that it has acquired ARGENE, a French company specialized in molecular diagnostics. This acquisition is bioMérieux’s tenth in the last five years.

World HAI Forum: Global Call to Action to Fight Antibiotic Resistance

30 June, 2011

Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics.

bioMérieux and Labor Berlin (Charité Vivantes GmbH) to Establish Center of Excellence in Laboratory Diagnostics

05 May, 2011

Labor Berlin and bioMérieux announce the signature of an agreement to create a Center of Excellence for microbiology and enhanced laboratory automation. The center will be located at Europe’s largest hospital laboratory, serving more than 8,000 in-house patients in Berlin and handling over 23 million patient analyses a year.

Ipsen and bioMérieux enter into a broad partnership in personalized medicine

25 February, 2011

The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care

bioTheranostics’ Breast Cancer IndexSM predicts risk for late recurrence in early stage ER-positive breast cancer patients

10 December, 2010

bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

bioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics

04 November, 2010

Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012. bioMérieux gains exclusive rights in microbiology. bioMérieux takes equity stake in Biocartis.

Pioneering diagnostics